Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Creative Realities Inc (CREX)
NASDAQInformation TechnologySoftware - ApplicationSnapshot 2026-11-04
$2.03-6.02%
Close 2026-11-05 · 1-day change
NASDAQInformation TechnologySoftware - ApplicationSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
0.09 → 0.09 EPS · FY ending Dec 31, 2027 · 2 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 2 to 2; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for CREX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
CDM acquisition drives revenue growth and pipeline strength | The company plans to use its CDM acquisition to boost sales. | Intact | No revenue growth or pipeline improvement from CDM in 2026 | Q3 rev >$23.9M vs target positive contribution Q2 record revenue surge; Q3 guidance to significantly exceed $23.9M as Albertsons rollout expands. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
CREX is a high-risk growth and acquisition-integration story, not yet a proven durable compounder, since it remains loss-making. The multi-year view is in a watch state: revenue has grown, but recent performance and momentum have weakened.
The valuation evidence describes CREX as cheap versus peers, with a justified pricing tag and low fragility. However, model confidence is low, and the negative expectations gap suggests the market setup is not simply an overlooked opportunity.
Near term, the risk of another earnings miss is elevated, following recent misses and a guidance-related concern. Over the multi-year view, revenue growth and modest margin progress support the thesis, while CDM integration remains mixed: reported cost savings are progressing toward management’s target, but its contribution has varied.
The key test is whether CREX delivers stronger sales guidance and continues improving margins while advancing CDM synergies. A guidance cut would add pressure to the thesis; easier interest rates or steadier results from large technology peers could improve the sector backdrop, but neither resolves company-specific execution risk.
Over the next 1 to 3 years, CREX offers a growth-and-integration thesis with signs of progress, but consecutive misses, losses, and high risk leave execution as the central question. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in Creative Realities Inc's published investment case. The stated target is Continued share repurchases in 2026. |
| Intact |
| No share buybacks or capital discipline in 2026 |
Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Margins improve through cost control and operational leverage in 2026 | Management wants to improve profit margins in 2026. | Improving | Operating loss worsens or stays below -$6 million in FY26 | Operating income: $-2.745M FY2026-Q2; GAAP. Published target: Operating margin improves from -$6.2M loss in Q1 2026. Annual target cannot be compared with a quarterly or TTM observation. Aug 14, 2026-2,745,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue reaches about $22 million in Q2 2026 | Creative Realities aims to grow revenue to about $22 million next quarter. | Improving | Revenue falls below $21 million in 2026-Q2 | Revenue: $21.505M FY2026-Q2; GAAP. Published target: ~$22M. The target does not explicitly identify fiscal versus calendar quarters. Aug 14, 202621,505,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: ““Compared to both last year and the first quarter of fiscal 2026, we saw revenue expansion, margin improvement, and increased Adjusted EBITDA.” ““We expect fiscal 2026 to be our best year ever and anticipate higher top line growth and expanded margins as we leverage the entire organization to achieve improved financial results.” Revenue was $21.505 million in 2026-Q2. Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.24 → $0.09 · observed estimates
$0.11B → $0.11B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $0.24 | $114,341,667 | 2 / 3 |
| 2026-07-25 | $0.24 | $114,341,667 | 2 / 3 |
| 2026-07-26 | $0.24 | $114,341,667 | 2 / 3 |
| 2026-07-27 | $0.24 | $114,341,667 | 2 / 3 |
| 2026-07-28 | $0.15 | $114,341,667 | 2 / 3 |
| 2026-07-29 | $-0.08 | $114,341,670 | 3 / 3 |
| 2026-07-30 | $-0.08 | $114,341,670 | 3 / 3 |
| 2026-07-31 | $0.15 | $114,341,667 | 2 / 3 |
| 2026-08-01 | $0.15 | $114,341,667 | 2 / 3 |
| 2026-08-02 | $-0.08 | $114,341,670 | 3 / 3 |
| 2026-08-03 | $-0.08 | $114,341,670 | 3 / 3 |
| 2026-08-04 | $-0.08 | $114,341,670 | 3 / 3 |
| 2026-08-05 | $0.15 | $114,341,667 | 2 / 3 |
| 2026-08-06 | $-0.08 | $114,341,670 | 3 / 3 |
| 2026-08-07 | $0.15 | $114,341,667 | 2 / 3 |
| 2026-08-08 | $-0.08 | $114,341,670 | 3 / 3 |
| 2026-08-09 | $-0.08 | $114,341,670 | 3 / 3 |
| 2026-08-10 | $-0.08 | $114,341,670 | 3 / 3 |
| 2026-08-11 | $-0.08 | $114,341,670 | 3 / 3 |
| 2026-08-12 | $0.15 | $114,341,667 | 2 / 3 |
| 2026-08-13 | $0.15 | $114,341,667 | 2 / 3 |
| 2026-08-14 | $0.15 | $114,341,667 | 2 / 3 |
| 2026-08-15 | $0.15 | $114,341,667 | 2 / 3 |
| 2026-08-16 | $0.15 | $114,341,667 | 2 / 3 |
| 2026-08-17 | $0.15 | $114,341,667 | 2 / 3 |
| 2026-08-18 | $0.15 | $114,341,667 | 2 / 3 |
| 2026-08-19 | $0.15 | $114,341,667 | 2 / 3 |
| 2026-08-20 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-08-21 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-08-22 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-08-23 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-08-24 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-08-25 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-08-26 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-08-27 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-08-28 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-08-29 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-08-30 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-08-31 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-09-01 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-09-02 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-09-03 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-09-04 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-09-05 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-09-06 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-09-07 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-09-08 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-09-09 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-09-10 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-09-11 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-09-12 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-09-13 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-09-14 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-09-15 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-09-16 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-09-17 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-09-18 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-09-19 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-09-20 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-09-21 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-09-22 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-09-23 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-09-24 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-09-25 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-09-26 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-09-27 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-09-28 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-09-29 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-09-30 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-10-01 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-10-02 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-10-03 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-10-04 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-10-05 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-10-06 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-10-07 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-10-08 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-10-09 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-10-10 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-10-11 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-10-12 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-10-13 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-10-14 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-10-15 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-10-16 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-10-17 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-10-18 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-10-19 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-10-20 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-10-21 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-10-22 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-10-23 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-10-24 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-10-25 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-10-26 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-10-27 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-10-28 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-10-29 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-10-30 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-10-31 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-11-01 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-11-02 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-11-03 | $0.09 | $114,088,000 | 2 / 3 |
| 2026-11-04 | $0.09 | $114,088,000 | 2 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 3 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.